Salmonella enterica serovar typhimurium infection induces cyclooxygenase 2 expression in macrophages:: Involvement of Salmonella pathogenicity island 2

被引:49
作者
Uchiya, K [1 ]
Nikai, T [1 ]
机构
[1] Meijo Univ, Fac Pharm, Dept Microbiol, Tenpaku Ku, Nagoya, Aichi 4688503, Japan
关键词
D O I
10.1128/IAI.72.12.6860-6869.2004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Salmonella pathogenicity island 2 (SPI-2) is required for intramacrophage survival and systemic infection in mice. We have recently reported that Salmonella enterica causes activation of the protein kinase A (PKA) signaling pathway in a manner dependent on SPI-2, resulting in the upregulation of interleukin-10 expression in macrophages (K. Uchiya et al., Infect. Immun. 72:1964-1973, 2004). We show in the present study the involvement of SPI-2 in a signal transduction pathway that induces the expression of cyclooxygenase 2 (COX-2), an inducible enzyme involved in the synthesis of prostanoids. High levels of prostaglandin E-2 (PGE(2)) and prostacyclin (PGI(2)), which are known to activate the PKA signaling pathway via their receptors, were induced in J774 macrophages infected with wild-type Salmonella compared to a strain carrying a mutation in the spiC gene, located within SPI-2. The increased production of both prostanoids was dependent on COX-2. COX-2 expression was dose dependently blocked by treatment with a specific inhibitor of the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway, and the phosphorylation level of ERK1/2 was higher in macrophages infected with wild-type Salmonella compared to the spiC mutant. Taken together, these results indicate that Salmonella causes an SPI-2-dependent ERK1/2 activation that leads to increased COX-2 expression, resulting in the upregulation of PGE(2) and PGI(2) production in macrophages. A COX-2 inhibitor inhibited not only Salmonella-induced activation of the PKA signaling pathway but also growth of wild-type Salmonella within macrophages, suggesting that Salmonella utilizes the COX-2 pathway to survive within macrophages and that the mechanism involves activation of the PKA signaling pathway.
引用
收藏
页码:6860 / 6869
页数:10
相关论文
共 52 条
[1]   Prostanoid receptors of murine NIH 3T3 and RAW 264.7 cells - Structure and expression of the murine prostaglandin EP4 receptor gene [J].
Arakawa, T ;
Laneuville, O ;
Miller, CA ;
Lakkides, KM ;
Wingerd, BA ;
DeWitt, DL ;
Smith, WL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (47) :29569-29575
[2]   Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis [J].
Astiz, M ;
Saha, D ;
Lustbader, D ;
Lin, R ;
Rackow, E .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1996, 128 (06) :594-600
[3]  
Bath P.M, 1990, COMPREHENSIVE MED CH, VVolume 3, P643
[4]   Protein kinase A downregulates the phosphorylation of p47 phox in human neutrophils: A possible pathway for inhibition of the respiratory burst [J].
BengisGarber, C ;
Gruener, N .
CELLULAR SIGNALLING, 1996, 8 (04) :291-296
[5]   MODULATION OF MACROPHAGE FUNCTION BY TRANSFORMING GROWTH-FACTOR-BETA, INTERLEUKIN-4, AND INTERLEUKIN-10 [J].
BOGDAN, C ;
NATHAN, C .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 685 :713-739
[6]   Salmonella pathogenicity island 2 mediates protection of intracellular Salmonella from reactive nitrogen intermediates [J].
Chakravortty, D ;
Hansen-Wester, I ;
Hensel, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (09) :1155-1166
[7]   Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages [J].
Chen, BC ;
Chen, YH ;
Lin, WW .
IMMUNOLOGY, 1999, 97 (01) :124-129
[8]   Snare-mediated membrane fusion [J].
Chen, YA ;
Scheller, RH .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) :98-106
[9]   Macrophage-dependent induction of the Salmonella pathogenicity island 2 type III secretion system and its role in intracellular survival [J].
Cirillo, DM ;
Valdivia, RH ;
Monack, DM ;
Falkow, S .
MOLECULAR MICROBIOLOGY, 1998, 30 (01) :175-188
[10]  
COLEMAN RA, 1994, PHARMACOL REV, V46, P205